EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana

Johanna Åhsberg iD, Peter Puplampu, Augustine Kwashie, Joseph Oliver Commey, Vincent Jessey Ganu, Michael Amo Omari, Yaw Adusi-Poku, Åse Bengård Andersen, Ernest Kenu, Margaret Lartey, Isik Somuncu Johansen, Stephanie Bjerrum

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad316 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Johanna Åhsberg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Infectious Diseases, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: HIV Infections, Lipopolysaccharides, Tuberculosis, Point-of-Care Testing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Læge Agnethe Løvgreens legat, Torben og Alice Frimodts fond, A.P. Møller fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The lateral flow urine lipoarabinomannan assay, Determine TB LAM (Determine LAM), offers the potential for timely tuberculosis (TB) treatment among people with human immunodeficiency virus (PWH).

Methods

In this cluster-randomized trial, Determine LAM was made available with staff training with performance feedback at 3 hospitals in Ghana. Newly admitted PWH with a positive World Health Organization four-symptom screening for TB, severe illness, or advanced HIV were enrolled. The primary outcome was days from enrollment to TB treatment initiation. We also reported the proportion of patients with a TB diagnosis, initiating TB treatment, all-cause mortality, and Determine LAM uptake at 8 weeks.

Results

We enrolled 422 patients including 174 (41.2%) in the intervention group. The median CD4 count was 87 (interquartile range [IQR], 25–205) cells/μL, and 32.7% were on antiretroviral therapy. More patients were diagnosed with TB in the intervention compared with the control group: 59 (34.1%) versus 46 (18.7%) (P < .001). Time to TB treatment remained constant, but patients were more likely to initiate TB treatment (adjusted hazard ratio, 2.19 [95% CI, 1.60–3.00]) during the intervention. Of patients with a Determine LAM test available, 41 (25.3%) tested positive. Of those, 19 (46.3%) initiated TB treatment. Overall, 118 patients had died (28.2%) at 8 weeks of follow-up.

Conclusions

The Determine LAM intervention in real-world practice increased TB diagnosis and the probability of TB treatment but did not reduce time to treatment initiation. Despite high uptake, only half of the LAM-positive patients initiated TB treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLipopolysaccharidesTuberculosisPoint-of-Care TestingHumansMaleFemaleAdultGhanaMiddle AgedAntitubercular AgentsInpatients

Stichwörter der Autor:innen

Determine LAMHIVXpert MTB/RIFpoint-of-caretuberculosis

Substanzen

lipoarabinomannanLipopolysaccharidesAntitubercular Agents

Autor:innen und Institutionen

  • Research Center of Infectious Diseases, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Mycobacterial Centre for Research Southern Denmark, Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
  • International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark.
  • Department of Medicine & Therapeutics, Medical School, College of Health Sciences, University of Ghana, Accra, Ghana.
  • Department of Medicine, Tema General Hospital, Tema, Ghana.
  • Department of Medicine, Lekma Hospital, Teshie, Ghana.

ORCID-Profile: Johanna Åhsberg

Förderung

  • Læge Agnethe Løvgreens legat
  • Torben og Alice Frimodts fond
  • A.P. Møller fonden
  • University of Southern Denmark
  • Odense University Hospital
  • Strategic Research Council

Zitieren

APA

Åhsberg, J., Puplampu, P., Kwashie, A., Commey, J. O., Ganu, V. J., Omari, M. A., Adusi-Poku, Y., Andersen, Å. B., Kenu, E., Lartey, M., Johansen, I. S., & Bjerrum, S. (2023). Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad316

Vancouver

Åhsberg J, Puplampu P, Kwashie A, Commey JO, Ganu VJ, Omari MA, et al. Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad316

BibTeX
@article{hsberg2023,
  author = {Åhsberg, Johanna and Puplampu, Peter and Kwashie, Augustine and Commey, Joseph Oliver and Ganu, Vincent Jessey and Omari, Michael Amo and Adusi-Poku, Yaw and Andersen, Åse Bengård and Kenu, Ernest and Lartey, Margaret and Johansen, Isik Somuncu and Bjerrum, Stephanie},
  title = {Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad316}
}
Kostenlos starten →